Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic (Q44581629)

4 December 2017

title

Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic (English)

1 reference

4 December 2017

1 reference

1 reference

1 reference

2

1 reference

4 December 2017

Olivier Schwartz

9

0 references

Frédéric Tangy

series ordinal

10

object named as

Frédéric Tangy

1 reference

4 December 2017

6

Michèle Février

1 reference

4 December 2017

3

Chantal Combredet

1 reference

4 December 2017

5

Claude Ruffié

1 reference

4 December 2017

8

Samantha Brandler

1 reference

4 December 2017

4

Valérie Najburg

1 reference

4 December 2017

7

Nadège Cayet

1 reference

4 December 2017

Mathilde Guerbois

1

1 reference

4 December 2017

language of work or name

English

0 references

publication date

5 April 2009

1 reference

4 December 2017

1 reference

4 December 2017

volume

388

1 reference

4 December 2017

issue

1

1 reference

4 December 2017

page(s)

191-203

1 reference

Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Dendritic cells and the control of immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Interclade neutralization and enhancement of human immunodeficiency virus type 1 identified by an assay using HeLa cells expressing both CD4 receptor and CXCR4/CCR5 coreceptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Toll-dependent selection of microbial antigens for presentation by dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Ted Slavin's blood and the development of HBV vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Pediatric Measles Vaccine Expressing a Dengue Antigen Induces Durable Serotype-specific Neutralizing Antibodies to Dengue Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

HIV-specific IgG in cervicovaginal secretions of exposed HIV-uninfected female sexual partners of HIV-infected men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

HIV vaccine design and the neutralizing antibody problem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

MHC-I-restricted presentation of HIV-1 virion antigens without viral replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Virus-like particles as HIV-1 vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Efficient human immunodeficiency virus ( HIV)-1 Gag-Env pseudovirion formation elicited from mammalian cells by a canarypox HIV vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Monocyte-derived dendritic cells: development of a cellular processor for clinical applications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Measles virus infects human dendritic cells and blocks their allostimulatory properties for CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Measles virus-induced promotion of dendritic cell maturation by soluble mediators does not overcome the immunosuppressive activity of viral glycoproteins on the cell surface

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

HIV vaccine design: insights from live attenuated SIV vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Virus-like particles-universal molecular toolboxes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Dendritic cells cross-present HIV antigens from live as well as apoptotic infected CD4+ T lymphocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Lentivirus-like particles without reverse transcriptase elicit efficient immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Challenges to conducting HIV preventative vaccine trials with adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Immune mechanisms associated with protection from vaginal SIV challenge in rhesus monkeys infected with virulence-attenuated SHIV 89.6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Dendritic cells and HIV-specific CD4+ T cells: HIV antigen presentation, T-cell activation, and viral transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Decrease in measles virus-specific CD4 T cell memory in vaccinated subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Frequency of measles virus-specific CD4+ and CD8+ T cells in subjects seronegative or highly seropositive for measles vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Dynamics of viral RNA synthesis during measles virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Macaques vaccinated with live-attenuated SIV control replication of heterologous virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

HIV type 1 Gag virus-like particle budding from spheroplasts of Saccharomyces cerevisiae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Induction of maturation of human blood dendritic cell precursors by measles virus is associated with immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Toll-like receptor 3 promotes cross-priming to virus-infected cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Measles virus induces abnormal differentiation of CD40 ligand-activated human dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Measles virus induces functional TRAIL production by human dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Antibody neutralization and escape by HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Production and characterization of simian--human immunodeficiency virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Virus-like particles: designing an effective AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Distribution and three-dimensional structure of AIDS virus envelope spikes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Attenuated measles virus as a vaccine vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

7 January 2021

Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

7 January 2021

Chimeric measles viruses with a foreign envelope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.02.047

1 reference

7 January 2021

10.1016/J.VIROL.2009.02.047

Identifiers

DOI

1 reference

4 December 2017

1 reference